About Us

Overview

Improving the lives and outcomes of cancer patients.
Our Pipeline Targets Large Cancer Indications
Read More >
Dedicated to Improving the Treatment of Cancer
Read More >

Overview

Cascadian Therapeutics is a biotechnology company dedicated to the development of oncology products that can improve the lives and outcomes of cancer patients. Our goal is to discover, develop and commercialize novel compounds that have the potential to improve the lives and outcomes of cancer patients. Our most advanced product candidate is tucatinib (ONT-380), an orally active and selective small molecule HER2 inhibitor. We are also developing a Chk1 inhibitor as a preclinical product candidate.

Cascadian Therapeutics is headquartered in Seattle, Washington. The Company is traded on The NASDAQ Global Market under the symbol CASC.

Our Pipeline Targets Large Cancer Indications
Read More >
Dedicated to Improving the Treatment of Cancer
Read More >